Interactions between Ethionamide and Vincasar PFS

Ethionamide has a major potential interaction with Alcoholism.

The use of ethionamide is contraindicated in patients with severe liver damage. Like many other antituberculous agents, ethionamide is hepatotoxic. Transient elevations in bilirubin and serum SGOT (AST) and SGPT (ALT) have been reported in 5% of the patients treated with ethionamide. Hepatitis, with or without jaundice, has also been observed, particularly in patients with diabetes mellitus. Therapy with ethionamide should be administered cautiously in patients with liver disease, a history of alcoholism, or diabetes. Liver function tests should be measured at baseline and monthly during therapy, and ethionamide withdrawn at the first signs or symptoms suggestive of liver damage.

Ethionamide has a major potential interaction with Alcoholism.

Peripheral neuropathy has been associated with the use of ethionamide, but much less frequently than with isoniazid, a structurally related agent. Therapy with ethionamide should be administered cautiously in patients with preexisting peripheral neuropathy or risk factors for developing the condition, such as malnutrition, diabetes, and alcoholism. Pyridoxine (vitamin B6) at a dosage of 25 to 50 mg/day has been recommended to prevent or attenuate isoniazid-related peripheral neuropathy and may be considered for patients receiving ethionamide.

The vinCRIStine in Vincasar PFS has a moderate potential interaction with Bone Marrow Depression/Low Blood Counts.

Vincristine induces dose-related myelosuppression. Leukopenia, thrombocytopenia, and anemia have been reported, however vincristine does not appear to have a consistent or significant effect on platelets or red blood cells. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Therapy with vincristine should be administered cautiously in patients with compromised bone marrow reserve. Monitor complete blood counts prior to each dose. If Grade 3 or 4 neutropenia, thrombocytopenia, or anemia develops, consider a dose modification or reduction as well as supportive care measures.

The vinCRIStine in Vincasar PFS has a moderate potential interaction with Constipation.

Vincristine can cause constipation. Ileus, bowel obstruction, and colonic pseudo-obstruction have occurred. When using this agent in people at risk of constipation, appropriate measures should be instituted to prevent such complications. A routine prophylactic regimen against constipation is recommended for all patients receiving vincristine.

Ethionamide has a major potential interaction with Diabetes Mellitus.

Peripheral neuropathy has been associated with the use of ethionamide, but much less frequently than with isoniazid, a structurally related agent. Therapy with ethionamide should be administered cautiously in patients with preexisting peripheral neuropathy or risk factors for developing the condition, such as malnutrition, diabetes, and alcoholism. Pyridoxine (vitamin B6) at a dosage of 25 to 50 mg/day has been recommended to prevent or attenuate isoniazid-related peripheral neuropathy and may be considered for patients receiving ethionamide.

Ethionamide has a major potential interaction with Diabetes Mellitus.

The use of ethionamide is contraindicated in patients with severe liver damage. Like many other antituberculous agents, ethionamide is hepatotoxic. Transient elevations in bilirubin and serum SGOT (AST) and SGPT (ALT) have been reported in 5% of the patients treated with ethionamide. Hepatitis, with or without jaundice, has also been observed, particularly in patients with diabetes mellitus. Therapy with ethionamide should be administered cautiously in patients with liver disease, a history of alcoholism, or diabetes. Liver function tests should be measured at baseline and monthly during therapy, and ethionamide withdrawn at the first signs or symptoms suggestive of liver damage.

Ethionamide has a moderate potential interaction with Diabetes Mellitus.

The use of ethionamide has occasionally been associated with poor diabetic control. Patients with diabetes mellitus should be monitored more closely during therapy with ethionamide, and their antidiabetic regimen adjusted accordingly.

The vinCRIStine in Vincasar PFS has a moderate potential interaction with Fever.

Vincristine induces dose-related myelosuppression. Leukopenia, thrombocytopenia, and anemia have been reported, however vincristine does not appear to have a consistent or significant effect on platelets or red blood cells. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Therapy with vincristine should be administered cautiously in patients with compromised bone marrow reserve. Monitor complete blood counts prior to each dose. If Grade 3 or 4 neutropenia, thrombocytopenia, or anemia develops, consider a dose modification or reduction as well as supportive care measures.

The vinCRIStine in Vincasar PFS has a moderate potential interaction with Gastrointestinal Obstruction.

Vincristine can cause constipation. Ileus, bowel obstruction, and colonic pseudo-obstruction have occurred. When using this agent in people at risk of constipation, appropriate measures should be instituted to prevent such complications. A routine prophylactic regimen against constipation is recommended for all patients receiving vincristine.

The vinCRIStine in Vincasar PFS has a moderate potential interaction with Infection.

Vincristine induces mild, dose-related myelosuppression. The use of vincristine may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with vincristine. Clinical monitoring of hematopoetic function is recommended.

Ethionamide has a major potential interaction with Liver Disease.

Ethionamide is primarily metabolized by the liver. Patients with liver disease may be at greater risk for adverse effects from ethionamide due to decreased drug clearance. Dosage reductions are recommended in these patients.

Ethionamide has a major potential interaction with Liver Disease.

The use of ethionamide is contraindicated in patients with severe liver damage. Like many other antituberculous agents, ethionamide is hepatotoxic. Transient elevations in bilirubin and serum SGOT (AST) and SGPT (ALT) have been reported in 5% of the patients treated with ethionamide. Hepatitis, with or without jaundice, has also been observed, particularly in patients with diabetes mellitus. Therapy with ethionamide should be administered cautiously in patients with liver disease, a history of alcoholism, or diabetes. Liver function tests should be measured at baseline and monthly during therapy, and ethionamide withdrawn at the first signs or symptoms suggestive of liver damage.

The vinCRIStine in Vincasar PFS has a moderate potential interaction with Liver Disease.

Vincristine is primarily metabolized by the liver. The influence of severe hepatic impairment on the safety and efficacy of vincristine has not been evaluated. Additionally, fatal liver toxicity and elevated levels of aspartate aminotransferase have occurred in clinical trials. Vincristine should be reduced or interrupted if there is evidence of hepatic toxicity. Therapy with vincristine should be administered cautiously and dosages reduced in patients with compromised hepatic function. Close clinical monitoring of hepatic function is recommended.

Ethionamide has a major potential interaction with Malnourishment.

Peripheral neuropathy has been associated with the use of ethionamide, but much less frequently than with isoniazid, a structurally related agent. Therapy with ethionamide should be administered cautiously in patients with preexisting peripheral neuropathy or risk factors for developing the condition, such as malnutrition, diabetes, and alcoholism. Pyridoxine (vitamin B6) at a dosage of 25 to 50 mg/day has been recommended to prevent or attenuate isoniazid-related peripheral neuropathy and may be considered for patients receiving ethionamide.

The vinCRIStine in Vincasar PFS has a major potential interaction with Neurological Disorders.

The use of vincristine is contraindicated in patients with demyelinating conditions including Charcot-Marie-Tooth syndrome. Neurotoxicity associated with vincristine therapy is dose-related and frequently sequential. Sensorimotor (paresthesia, decreased deep- tendon reflex, ataxia, paralysis), autonomic (constipation and adynamic ileus), and CNS (mental status changes, seizures, coma) neurotoxicity have been reported. Patients with existing neuromuscular or neurologic diseases may be at increased risk for toxicity with vincristine therapy. Therapy with vincristine should be administered cautiously and dosage reduction considered in patients with neurologic dysfunction.

Ethionamide has a major potential interaction with Peripheral Neuropathy.

Peripheral neuropathy has been associated with the use of ethionamide, but much less frequently than with isoniazid, a structurally related agent. Therapy with ethionamide should be administered cautiously in patients with preexisting peripheral neuropathy or risk factors for developing the condition, such as malnutrition, diabetes, and alcoholism. Pyridoxine (vitamin B6) at a dosage of 25 to 50 mg/day has been recommended to prevent or attenuate isoniazid-related peripheral neuropathy and may be considered for patients receiving ethionamide.

The vinCRIStine in Vincasar PFS has a major potential interaction with Peripheral Neuropathy.

The use of vincristine is contraindicated in patients with demyelinating conditions including Charcot-Marie-Tooth syndrome. Neurotoxicity associated with vincristine therapy is dose-related and frequently sequential. Sensorimotor (paresthesia, decreased deep- tendon reflex, ataxia, paralysis), autonomic (constipation and adynamic ileus), and CNS (mental status changes, seizures, coma) neurotoxicity have been reported. Patients with existing neuromuscular or neurologic diseases may be at increased risk for toxicity with vincristine therapy. Therapy with vincristine should be administered cautiously and dosage reduction considered in patients with neurologic dysfunction.

The vinCRIStine in Vincasar PFS has a major potential interaction with Pulmonary Impairment.

Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids. These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose. Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction. Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids. In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.

The vinCRIStine in Vincasar PFS has a moderate potential interaction with Renal Dysfunction.

The influence of renal impairment on the safety, efficacy, and pharmacokinetics of vincristine has not been evaluated. Caution and monitoring of renal function is advised in patients with renal impairment.

The vinCRIStine in Vincasar PFS has a moderate potential interaction with SIADH.

A syndrome of sudden inappropriate antidiuretic hormone (SIADH) secretion has been reported rarely in association with the use of vincristine. Therapy with vincristine should be administered cautiously in patients with or predisposed to abnormal antidiuretic hormone release and/or suppression.